Bone Biologics Corp
BBLG
Last
$0.47
Day
-2.5%
1y
-82.6%
5y
-100.0%
52w
-83.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
0.51
EMA 50
0.64
EMA 200
1.65
20d high
-19.1%
5y high
-100.0%
5y range
0th
Positions held
Your positionsBBLG isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$0.53
Stop
$0.42
Stop distance
10.1%
Target vs last
+13.5%
Fundamentals
| Market cap | $1.29M | Enterprise value | -$2.74M | Trailing P/E | — | Forward P/E | -0.70 |
| PEG | — | Price / book | 0.22 | Beta | 0.57 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -55.0% | ROA | -33.5% | Debt / equity | — |
| Current ratio | 8.67 | Free cash flow | -$1.69M | Analyst recommendation | none | Mean target | $12.20 |
| 52w high | $2.76 | 52w low | $0.43 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$0.8M | -$0.8M | -$0.7M | -$0.7M | -$0.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | $0.0M | — | — | — | $0.0M | — |
| Operating income | -$0.8M | -$0.8M | -$0.7M | -$0.7M | -$0.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$3.1M | -$4.1M | -$8.9M | -$1.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | $0.0M | $0.0M |
| Operating income | -$3.2M | -$4.2M | -$9.4M | -$3.7M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Bone Biologics Expands Trial Sites
2026-09-03 · Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-17 · BBLG Efficiency Improves as Crucial Trials Advance
2026-08-12 · Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances
2026-08-12 · Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
2026-07-23 · Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Price (daily)
Full chart · RSI · MACD · patternsBBLG · daily-1.4% over 14 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin